BRIEF—Tecentriq secures positive UK reimbursement decision

Roche has won reimbursement in the UK for its immunotherapy Tecentriq (atezolizumab) as a second-line therapy for advanced bladder cancer.

The decision, which is the third straight positive outcome for Tecentriq from the UK’s health technology assessor NICE, means the drug will be available for routine use through the country’s national healthcare provider.

The decision is based on data from the Phase II/III IMvigor210 and IMvigor211 studies, demonstrating the clinical efficacy and safety of Tecentriq compared to therapies currently provided to patients in this setting.